Bell et al. [20] described heterozygous germline mutations in the CHEK2 gene in patients with Li-Fraumeni syndrome, suggesting that CHEK2 is a tumour suppressor gene whose loss of function confers predisposition to develop sarcoma, breast cancer, and brain tumours. The gene discussed is CHEK2; the disease is breast carcinoma.